SlideShare a Scribd company logo
Dr. Pankaj Gupta
October 2007 meeting was organized at National
Cancer Institute (NCI), Bethesda, to address the
terminology and other issues in thyroid FNA
Idea behind uniform reporting system
• Facilitate effective communication among cytopathologist, radiologist,
endocrinologist and surgeon
• Facilitate Histocytological correlation for thyroid disease
• Facilitate research into epidemiology, molecular biology, pathology and
diagnosis of thyroid diseases
• Allow easy and reliable sharing of data from different laboratories for
national and international collaboration studies
Format of report
• Each report begin with six general categories
• Some categories have two alternative names as the consensus was
not reached at NCI conference on single name
• Each categories has implied cancer risk ( ranging from 0 to 3% for
benign categories to virtually 100% for malignant)
• Additional descriptive comments beyond such subcategorization are
optinal and left to discretion of pathologist
Recommended diagnostic categories
1. Non Diagnostic or Unsatisfactory (ND/UNS)
- Cystic fluid only
- Virtually acellular specimen
- Other (obscuring blood, clotting artifacts)
Recommended diagnostic categories
2. Benign
- Consistent with benign follicular nodule
- Consistent with lymphocytic ( Hashimoto’s thyroiditis)
in proper clinical context
- Consistent with granulomatous (sub acute) thyroiditis
- Others
Recommended diagnostic categories
3. Atypia of Undetermined significance or Follicular lesion
of undermined significance (AUS/FLUS)
Recommended diagnostic categories
4. Follicular neoplasm or Suspicious for Follicular
neoplasm (Specify if Hurthle cell or Oncocytic type)
Recommended diagnostic categories
5. Suspicious for malignancy
- Suspicious for Papillary carcinoma
- Suspicious for Medullary carcinoma
- Suspicious for Metastatic carcinoma
- Suspicious for Lymphoma
- Others
Recommended diagnostic categories
6. Malignant
- Papillary thyroid carcinoma
- Poorly differentiated carcinoma
- Medullary thyroid carcinoma
- Undifferentiated ( Anaplastic ) carcinoma
- Squamous cell carcinoma
- Carcinoma with mixed features
- Metastatic carcinoma
- Non Hodgkin lymphoma
- Others
CATEGORY I (Non Diagnostic or Unsatisfactory)
Causes of Unsatisfactory smears
- Obscuring blood
- Overly thick smears
- Air drying of alcohol fixed smears
- Inadequate number of follicular cells
Criteria for adequacy
• At least six groups of benign follicular cells is required with each
group composed of at least 10 cells.
• Any specimen that contain abundant colloid is considered
adequate
• When a specific diagnosis (e.g. Lymphocytic thyroiditis) can be
given or when there is any atypia specimen is by definition
adequate
• Specimen containing cyst macrophages only are kept under
ND/UNS
• Unless specified in report specimen is considered adequate
Category II ( Benign)
• An adequate cellular specimen composed of varying proportion of
colloid and benign follicular cells arranged in macro follicles or
macrofollicular fragments are considered as benign follicular
nodule
• If nodule shows significant growth or suspicious radiological
features then, a repeat FNA is considered
• Other benign categories include Hashimoto thyroiditis,
Granulomatous thyroiditis
• Infections, amyloid, black thyroid, reactive changes can be
mentioned as descriptive diagnosis
Category III ( AUS/ FLUS)
Most common scenarios for this categorization are
• Prominent population of micro follicles in an aspirate that does
not otherwise fulfill the criteria for follicular neoplasm
• Predominance of Hurthle cell in a sparsely cellular smear with
scant colloid
• Interpretation of follicular cell atypia is hindered by air drying or
clotting artifacts
• A moderately or markedly cellular smear consisting of exclusive
population of Hurthle cells yet clinical setting suggest a benign
Hurthle cell nodule ( Lymphocytic thyroiditis, Multi nodular goiter)
• There are focal features suggestive of Papillary carcinoma
including nuclear grooves, enlarged nuclei with pale chromatin in
an other wise predominantly benign appearing sample. ( these
can be cyst lining cells)
• A minor population of follicular cells may show nuclear
enlargement often accompanied by prominent nucleoli
(radioactive iodine, carbamizole, cystic degeneration or
hemorrhage)
• There is atypical lymphoid infiltrate but degree of atypia is not
sufficient to categorize it as Suspicious for malignancy
• It is important that only nodules with atypical undetermined
significance should be placed in this category
• Recognizable benign changes like Hurthle cell change, Black
thyroid, Radiation changes should not be classified as AUS
• A moderate or markedly cellular specimen without any significant
nuclear or architectural atypia does not qualify for AUS
Category IV (FN/SFN)
• Purpose of this category is to identify a nodule that might be a
follicular carcinoma and triage it for surgical lobectomy
• Term suspicious for Follicular neoplasm is preferred over Follicular
neoplasm because a significant proportion of cases prove out to be
hyperplastic proliferation of follicular cells, most commonly those
of multi nodular goiter.
• Hallmark of this category is disturbed architecture – Follicular cells
predominantly arranges in micro follicles or trabeculae.
• Cytological preparations typically have high cellularity and scant to
absent colloid
• Cellular crowding and overlapping are conspicuous and follicular
cells are usually larger than normal
• Nuclear pleomorphism, and mitosis are uncommon
• Cases that demonstrate nuclear features of Papillary carcinoma are
excluded from this category
• If sample is cellular and mostly macro follicles benign interpretation
is appropriate
Category V (Suspicious for malignancy)
• If only 1 or 2 characteristics of malignancy are present, if they are
only focal or if sample is sparsely cellular and a malignant diagnosis
cannot be made with certainty
Category VI (Malignant)
• This category is used whenever cytomorphological features are
conclusive for malignancy
• Descriptive comments that follow are used to sub classify
malignancy and to summarize the results of special studies if any
DIAGNOSTIC CATEGORY RISK OF MALIGNANCY USUAL MANAGEMENT
ND/ UNS 1-4 % Repeat FNA with ultrasound
guidance
Benign 0-3 % Clinical Follow up
AUS/ FLUS 5-15% Repeat FNA
FN/ SFN 15-30% Surgical lobectomy
Suspicious for Malignancy 60-75% Near total thyroidectomy /
Surgical lobectomy
Malignant 97-99% Near total thyroidectomy
Bethesda thyroid

More Related Content

What's hot

Grossing thyroid gland
Grossing thyroid glandGrossing thyroid gland
Grossing thyroid gland
Sansar Babu Tiwari
 
Non hodgkin lymphoma
Non hodgkin lymphomaNon hodgkin lymphoma
Non hodgkin lymphoma
tashagarwal
 
CYTOLOGY OF BREAST LESIONS??!
CYTOLOGY OF BREAST LESIONS??! CYTOLOGY OF BREAST LESIONS??!
CYTOLOGY OF BREAST LESIONS??!
Ashish Jawarkar
 
Patterns in histopathology
Patterns in histopathologyPatterns in histopathology
Patterns in histopathology
Ankita Baghel
 
Ihc oncology.ppt1
Ihc oncology.ppt1Ihc oncology.ppt1
Ihc oncology.ppt1
Dr ABDUL WAHEED DAR
 
cytology of the breast
cytology of the breastcytology of the breast
cytology of the breast
Hayelom kassaye
 
Bethesda 180521085301
Bethesda 180521085301Bethesda 180521085301
Bethesda 180521085301
johannesendjala
 
Gross of thyroid gland
Gross of thyroid glandGross of thyroid gland
Gross of thyroid gland
Monika Nema
 
Fnac of salivary gland tumour
Fnac of salivary gland tumourFnac of salivary gland tumour
Fnac of salivary gland tumour
aghara mahesh
 
Whipple's specimen grossing
Whipple's  specimen grossingWhipple's  specimen grossing
Whipple's specimen grossing
Dr.Pooja Dwivedi
 
THYROID MALIGNANCIES
THYROID MALIGNANCIESTHYROID MALIGNANCIES
THYROID MALIGNANCIES
PGIMER Chandigarh
 
Role of ihc on soft tissue tumours
Role of ihc on soft tissue tumoursRole of ihc on soft tissue tumours
Role of ihc on soft tissue tumours
ariva zhagan
 
Endometrial stromal tumours revisited
Endometrial stromal tumours revisitedEndometrial stromal tumours revisited
Endometrial stromal tumours revisited
drtousif
 
grossing of Colorectal specimens
grossing of Colorectal specimensgrossing of Colorectal specimens
grossing of Colorectal specimens
Anam Khurshid
 
PATHOLOGY OF THYROID CANCERS.pptx
PATHOLOGY OF THYROID CANCERS.pptxPATHOLOGY OF THYROID CANCERS.pptx
PATHOLOGY OF THYROID CANCERS.pptx
RAKHIJHA23
 
Effusion cytology - Diagnosis.
Effusion cytology - Diagnosis.Effusion cytology - Diagnosis.
Effusion cytology - Diagnosis.
namrathrs87
 
Classification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinalClassification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinal
Indira Shastry
 
Efficacy of liquid based cytology versus conventional smears
Efficacy of liquid based cytology versus conventional smearsEfficacy of liquid based cytology versus conventional smears
Efficacy of liquid based cytology versus conventional smears
Anamika Dev
 

What's hot (20)

Grossing thyroid gland
Grossing thyroid glandGrossing thyroid gland
Grossing thyroid gland
 
Non hodgkin lymphoma
Non hodgkin lymphomaNon hodgkin lymphoma
Non hodgkin lymphoma
 
Thyroid Tumors
Thyroid TumorsThyroid Tumors
Thyroid Tumors
 
CYTOLOGY OF BREAST LESIONS??!
CYTOLOGY OF BREAST LESIONS??! CYTOLOGY OF BREAST LESIONS??!
CYTOLOGY OF BREAST LESIONS??!
 
Patterns in histopathology
Patterns in histopathologyPatterns in histopathology
Patterns in histopathology
 
Fnac breast
Fnac breastFnac breast
Fnac breast
 
Ihc oncology.ppt1
Ihc oncology.ppt1Ihc oncology.ppt1
Ihc oncology.ppt1
 
cytology of the breast
cytology of the breastcytology of the breast
cytology of the breast
 
Bethesda 180521085301
Bethesda 180521085301Bethesda 180521085301
Bethesda 180521085301
 
Gross of thyroid gland
Gross of thyroid glandGross of thyroid gland
Gross of thyroid gland
 
Fnac of salivary gland tumour
Fnac of salivary gland tumourFnac of salivary gland tumour
Fnac of salivary gland tumour
 
Whipple's specimen grossing
Whipple's  specimen grossingWhipple's  specimen grossing
Whipple's specimen grossing
 
THYROID MALIGNANCIES
THYROID MALIGNANCIESTHYROID MALIGNANCIES
THYROID MALIGNANCIES
 
Role of ihc on soft tissue tumours
Role of ihc on soft tissue tumoursRole of ihc on soft tissue tumours
Role of ihc on soft tissue tumours
 
Endometrial stromal tumours revisited
Endometrial stromal tumours revisitedEndometrial stromal tumours revisited
Endometrial stromal tumours revisited
 
grossing of Colorectal specimens
grossing of Colorectal specimensgrossing of Colorectal specimens
grossing of Colorectal specimens
 
PATHOLOGY OF THYROID CANCERS.pptx
PATHOLOGY OF THYROID CANCERS.pptxPATHOLOGY OF THYROID CANCERS.pptx
PATHOLOGY OF THYROID CANCERS.pptx
 
Effusion cytology - Diagnosis.
Effusion cytology - Diagnosis.Effusion cytology - Diagnosis.
Effusion cytology - Diagnosis.
 
Classification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinalClassification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinal
 
Efficacy of liquid based cytology versus conventional smears
Efficacy of liquid based cytology versus conventional smearsEfficacy of liquid based cytology versus conventional smears
Efficacy of liquid based cytology versus conventional smears
 

Viewers also liked

Bethesda System for thyroid cytopathology
Bethesda System for thyroid cytopathologyBethesda System for thyroid cytopathology
Bethesda System for thyroid cytopathology
Precky Gabuat
 
color atlas on bethesda system for reporting thyroid cytology
color atlas on bethesda system for reporting thyroid cytologycolor atlas on bethesda system for reporting thyroid cytology
color atlas on bethesda system for reporting thyroid cytology
Ashish Jawarkar
 
2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)
2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)
2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)
Jeremy F. Robles MD, FPCP, FPSEM
 
Thin prep morphology (Cervical cytology)
Thin prep morphology (Cervical cytology)Thin prep morphology (Cervical cytology)
Thin prep morphology (Cervical cytology)
Ashish Jawarkar
 
Cellular adaptations, injury and death.. Lecture 1
Cellular adaptations, injury and death.. Lecture 1Cellular adaptations, injury and death.. Lecture 1
Cellular adaptations, injury and death.. Lecture 1
Ashish Jawarkar
 
Interpretation of histograms
Interpretation of histogramsInterpretation of histograms
Interpretation of histograms
Pankaj Gupta
 
Cytotechniques
Cytotechniques  Cytotechniques
Cytotechniques
drtousif
 
Exfoliative cytology
Exfoliative cytologyExfoliative cytology
Exfoliative cytology
Rajanna Venkatraman
 
Cell block and liquid based cytology
Cell block and liquid based cytologyCell block and liquid based cytology
Cell block and liquid based cytologyDr Neha Mahajan
 
Interpretation of Pathology Reports in Biopsies for Dermatitis
Interpretation of Pathology Reports in Biopsies for DermatitisInterpretation of Pathology Reports in Biopsies for Dermatitis
Interpretation of Pathology Reports in Biopsies for Dermatitis
Marco Fusaro
 
dr talal anaplastic cancer 2
dr talal anaplastic cancer 2dr talal anaplastic cancer 2
dr talal anaplastic cancer 2talal mohamed
 
Thpt
ThptThpt
Thyroid Overview
Thyroid OverviewThyroid Overview
Thyroid OverviewMiami Dade
 
Tireoide zona cinzenta.
Tireoide zona cinzenta.Tireoide zona cinzenta.
Tireoide zona cinzenta.
Jamile Barbosa
 
Poorly differenciated thyroid carcinoma
Poorly differenciated thyroid carcinomaPoorly differenciated thyroid carcinoma
Poorly differenciated thyroid carcinoma
ikramdr01
 

Viewers also liked (15)

Bethesda System for thyroid cytopathology
Bethesda System for thyroid cytopathologyBethesda System for thyroid cytopathology
Bethesda System for thyroid cytopathology
 
color atlas on bethesda system for reporting thyroid cytology
color atlas on bethesda system for reporting thyroid cytologycolor atlas on bethesda system for reporting thyroid cytology
color atlas on bethesda system for reporting thyroid cytology
 
2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)
2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)
2013 4-14 CDO TEPI - thyroid nodules and cancer (Case Based Approach)
 
Thin prep morphology (Cervical cytology)
Thin prep morphology (Cervical cytology)Thin prep morphology (Cervical cytology)
Thin prep morphology (Cervical cytology)
 
Cellular adaptations, injury and death.. Lecture 1
Cellular adaptations, injury and death.. Lecture 1Cellular adaptations, injury and death.. Lecture 1
Cellular adaptations, injury and death.. Lecture 1
 
Interpretation of histograms
Interpretation of histogramsInterpretation of histograms
Interpretation of histograms
 
Cytotechniques
Cytotechniques  Cytotechniques
Cytotechniques
 
Exfoliative cytology
Exfoliative cytologyExfoliative cytology
Exfoliative cytology
 
Cell block and liquid based cytology
Cell block and liquid based cytologyCell block and liquid based cytology
Cell block and liquid based cytology
 
Interpretation of Pathology Reports in Biopsies for Dermatitis
Interpretation of Pathology Reports in Biopsies for DermatitisInterpretation of Pathology Reports in Biopsies for Dermatitis
Interpretation of Pathology Reports in Biopsies for Dermatitis
 
dr talal anaplastic cancer 2
dr talal anaplastic cancer 2dr talal anaplastic cancer 2
dr talal anaplastic cancer 2
 
Thpt
ThptThpt
Thpt
 
Thyroid Overview
Thyroid OverviewThyroid Overview
Thyroid Overview
 
Tireoide zona cinzenta.
Tireoide zona cinzenta.Tireoide zona cinzenta.
Tireoide zona cinzenta.
 
Poorly differenciated thyroid carcinoma
Poorly differenciated thyroid carcinomaPoorly differenciated thyroid carcinoma
Poorly differenciated thyroid carcinoma
 

Similar to Bethesda thyroid

Bethesda updates with Thyroid path 2023.pptx
Bethesda updates with Thyroid path 2023.pptxBethesda updates with Thyroid path 2023.pptx
Bethesda updates with Thyroid path 2023.pptx
DivyaTiwari722899
 
Thyroid Neoplasms an update based on latest WHO
Thyroid Neoplasms an update based on latest WHOThyroid Neoplasms an update based on latest WHO
Thyroid Neoplasms an update based on latest WHO
Vivekanand A
 
BETHESDA THYROID 2023 updates only .pptx
BETHESDA THYROID 2023 updates only .pptxBETHESDA THYROID 2023 updates only .pptx
BETHESDA THYROID 2023 updates only .pptx
FraishuFrancis1
 
Cytohistological Correlation Of Malignant Thyroid Lesions
Cytohistological Correlation Of Malignant Thyroid LesionsCytohistological Correlation Of Malignant Thyroid Lesions
Cytohistological Correlation Of Malignant Thyroid Lesions
Dr.Pooja Dwivedi
 
bethesda system of thyroid cytopathology.pptx
bethesda system of thyroid cytopathology.pptxbethesda system of thyroid cytopathology.pptx
bethesda system of thyroid cytopathology.pptx
anweshaagarwal1
 
Thyroid 2017
Thyroid 2017Thyroid 2017
Thyroid 2017
Manan Shah
 
UPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptx
UPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptxUPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptx
UPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptx
jenishJebadurai1
 
Follicular thyroid differential diagnosis
Follicular thyroid differential diagnosisFollicular thyroid differential diagnosis
Follicular thyroid differential diagnosis
Vikram Prabhakar
 
CANCER: A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSIS
CANCER:  A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSISCANCER:  A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSIS
CANCER: A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSIS
Charu Pundir
 
germ cell tumours of ovary
germ cell tumours of ovarygerm cell tumours of ovary
germ cell tumours of ovary
Sreelasya Kakarla
 
Approach to thyroid cancer
Approach to thyroid cancerApproach to thyroid cancer
Approach to thyroid cancer
MohammedAlHinai18
 
Carcinoma of Unknown Primary (COUP)
Carcinoma of Unknown Primary (COUP)Carcinoma of Unknown Primary (COUP)
Carcinoma of Unknown Primary (COUP)
Dr.Shriniwas Bhawana Rishi
 
Dealing with ATYPIA and papillary lesions in IN BREAST
Dealing with ATYPIA and papillary lesions in IN BREASTDealing with ATYPIA and papillary lesions in IN BREAST
Dealing with ATYPIA and papillary lesions in IN BREAST
sadiya97
 
paris presentation.pptx
paris presentation.pptxparis presentation.pptx
paris presentation.pptx
KarishmaBhuyan
 
WHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptx
WHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptxWHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptx
WHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptx
SURAJ PANCHAL
 
Solitary thyroid nodule
Solitary thyroid nodule Solitary thyroid nodule
Solitary thyroid nodule
Jaydeep Malakar
 
An introduction to thyroid neoplasms
An introduction to thyroid neoplasmsAn introduction to thyroid neoplasms
An introduction to thyroid neoplasms
hosam hamza
 
Testis lymphoma RA 25-1.pptx
Testis lymphoma RA 25-1.pptxTestis lymphoma RA 25-1.pptx
Testis lymphoma RA 25-1.pptx
Ravi Kothari
 
TB System ReportingThyroid Cytopathology
TB System ReportingThyroid CytopathologyTB System ReportingThyroid Cytopathology
TB System ReportingThyroid Cytopathology
aamanimutakani
 

Similar to Bethesda thyroid (20)

Bethesda updates with Thyroid path 2023.pptx
Bethesda updates with Thyroid path 2023.pptxBethesda updates with Thyroid path 2023.pptx
Bethesda updates with Thyroid path 2023.pptx
 
Thyroid Neoplasms an update based on latest WHO
Thyroid Neoplasms an update based on latest WHOThyroid Neoplasms an update based on latest WHO
Thyroid Neoplasms an update based on latest WHO
 
BETHESDA THYROID 2023 updates only .pptx
BETHESDA THYROID 2023 updates only .pptxBETHESDA THYROID 2023 updates only .pptx
BETHESDA THYROID 2023 updates only .pptx
 
Cytohistological Correlation Of Malignant Thyroid Lesions
Cytohistological Correlation Of Malignant Thyroid LesionsCytohistological Correlation Of Malignant Thyroid Lesions
Cytohistological Correlation Of Malignant Thyroid Lesions
 
bethesda system of thyroid cytopathology.pptx
bethesda system of thyroid cytopathology.pptxbethesda system of thyroid cytopathology.pptx
bethesda system of thyroid cytopathology.pptx
 
Thyroid 2017
Thyroid 2017Thyroid 2017
Thyroid 2017
 
UPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptx
UPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptxUPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptx
UPDATES IN THE BETHESDA SYSTEM FOR REPORTING THYROID.pptx
 
Follicular thyroid differential diagnosis
Follicular thyroid differential diagnosisFollicular thyroid differential diagnosis
Follicular thyroid differential diagnosis
 
CANCER: A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSIS
CANCER:  A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSISCANCER:  A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSIS
CANCER: A REVIEW: WORLD'S SECOND MOST FEARED DIAGNOSIS
 
germ cell tumours of ovary
germ cell tumours of ovarygerm cell tumours of ovary
germ cell tumours of ovary
 
Approach to thyroid cancer
Approach to thyroid cancerApproach to thyroid cancer
Approach to thyroid cancer
 
Carcinoma of Unknown Primary (COUP)
Carcinoma of Unknown Primary (COUP)Carcinoma of Unknown Primary (COUP)
Carcinoma of Unknown Primary (COUP)
 
Dealing with ATYPIA and papillary lesions in IN BREAST
Dealing with ATYPIA and papillary lesions in IN BREASTDealing with ATYPIA and papillary lesions in IN BREAST
Dealing with ATYPIA and papillary lesions in IN BREAST
 
paris presentation.pptx
paris presentation.pptxparis presentation.pptx
paris presentation.pptx
 
Principles of Oncology
Principles of OncologyPrinciples of Oncology
Principles of Oncology
 
WHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptx
WHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptxWHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptx
WHO CLASSIFICATION 2016 RENAL CELL CARCINOMA.pptx
 
Solitary thyroid nodule
Solitary thyroid nodule Solitary thyroid nodule
Solitary thyroid nodule
 
An introduction to thyroid neoplasms
An introduction to thyroid neoplasmsAn introduction to thyroid neoplasms
An introduction to thyroid neoplasms
 
Testis lymphoma RA 25-1.pptx
Testis lymphoma RA 25-1.pptxTestis lymphoma RA 25-1.pptx
Testis lymphoma RA 25-1.pptx
 
TB System ReportingThyroid Cytopathology
TB System ReportingThyroid CytopathologyTB System ReportingThyroid Cytopathology
TB System ReportingThyroid Cytopathology
 

Recently uploaded

Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 

Recently uploaded (20)

Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 

Bethesda thyroid

  • 2. October 2007 meeting was organized at National Cancer Institute (NCI), Bethesda, to address the terminology and other issues in thyroid FNA
  • 3. Idea behind uniform reporting system • Facilitate effective communication among cytopathologist, radiologist, endocrinologist and surgeon • Facilitate Histocytological correlation for thyroid disease • Facilitate research into epidemiology, molecular biology, pathology and diagnosis of thyroid diseases • Allow easy and reliable sharing of data from different laboratories for national and international collaboration studies
  • 4. Format of report • Each report begin with six general categories • Some categories have two alternative names as the consensus was not reached at NCI conference on single name • Each categories has implied cancer risk ( ranging from 0 to 3% for benign categories to virtually 100% for malignant) • Additional descriptive comments beyond such subcategorization are optinal and left to discretion of pathologist
  • 5. Recommended diagnostic categories 1. Non Diagnostic or Unsatisfactory (ND/UNS) - Cystic fluid only - Virtually acellular specimen - Other (obscuring blood, clotting artifacts)
  • 6. Recommended diagnostic categories 2. Benign - Consistent with benign follicular nodule - Consistent with lymphocytic ( Hashimoto’s thyroiditis) in proper clinical context - Consistent with granulomatous (sub acute) thyroiditis - Others
  • 7. Recommended diagnostic categories 3. Atypia of Undetermined significance or Follicular lesion of undermined significance (AUS/FLUS)
  • 8. Recommended diagnostic categories 4. Follicular neoplasm or Suspicious for Follicular neoplasm (Specify if Hurthle cell or Oncocytic type)
  • 9. Recommended diagnostic categories 5. Suspicious for malignancy - Suspicious for Papillary carcinoma - Suspicious for Medullary carcinoma - Suspicious for Metastatic carcinoma - Suspicious for Lymphoma - Others
  • 10. Recommended diagnostic categories 6. Malignant - Papillary thyroid carcinoma - Poorly differentiated carcinoma - Medullary thyroid carcinoma - Undifferentiated ( Anaplastic ) carcinoma - Squamous cell carcinoma - Carcinoma with mixed features - Metastatic carcinoma - Non Hodgkin lymphoma - Others
  • 11. CATEGORY I (Non Diagnostic or Unsatisfactory) Causes of Unsatisfactory smears - Obscuring blood - Overly thick smears - Air drying of alcohol fixed smears - Inadequate number of follicular cells
  • 12. Criteria for adequacy • At least six groups of benign follicular cells is required with each group composed of at least 10 cells. • Any specimen that contain abundant colloid is considered adequate • When a specific diagnosis (e.g. Lymphocytic thyroiditis) can be given or when there is any atypia specimen is by definition adequate
  • 13. • Specimen containing cyst macrophages only are kept under ND/UNS • Unless specified in report specimen is considered adequate
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19. Category II ( Benign) • An adequate cellular specimen composed of varying proportion of colloid and benign follicular cells arranged in macro follicles or macrofollicular fragments are considered as benign follicular nodule • If nodule shows significant growth or suspicious radiological features then, a repeat FNA is considered
  • 20. • Other benign categories include Hashimoto thyroiditis, Granulomatous thyroiditis • Infections, amyloid, black thyroid, reactive changes can be mentioned as descriptive diagnosis
  • 21.
  • 22.
  • 23.
  • 24. Category III ( AUS/ FLUS) Most common scenarios for this categorization are • Prominent population of micro follicles in an aspirate that does not otherwise fulfill the criteria for follicular neoplasm • Predominance of Hurthle cell in a sparsely cellular smear with scant colloid • Interpretation of follicular cell atypia is hindered by air drying or clotting artifacts
  • 25. • A moderately or markedly cellular smear consisting of exclusive population of Hurthle cells yet clinical setting suggest a benign Hurthle cell nodule ( Lymphocytic thyroiditis, Multi nodular goiter) • There are focal features suggestive of Papillary carcinoma including nuclear grooves, enlarged nuclei with pale chromatin in an other wise predominantly benign appearing sample. ( these can be cyst lining cells)
  • 26. • A minor population of follicular cells may show nuclear enlargement often accompanied by prominent nucleoli (radioactive iodine, carbamizole, cystic degeneration or hemorrhage) • There is atypical lymphoid infiltrate but degree of atypia is not sufficient to categorize it as Suspicious for malignancy
  • 27. • It is important that only nodules with atypical undetermined significance should be placed in this category • Recognizable benign changes like Hurthle cell change, Black thyroid, Radiation changes should not be classified as AUS • A moderate or markedly cellular specimen without any significant nuclear or architectural atypia does not qualify for AUS
  • 28. Category IV (FN/SFN) • Purpose of this category is to identify a nodule that might be a follicular carcinoma and triage it for surgical lobectomy • Term suspicious for Follicular neoplasm is preferred over Follicular neoplasm because a significant proportion of cases prove out to be hyperplastic proliferation of follicular cells, most commonly those of multi nodular goiter. • Hallmark of this category is disturbed architecture – Follicular cells predominantly arranges in micro follicles or trabeculae.
  • 29. • Cytological preparations typically have high cellularity and scant to absent colloid • Cellular crowding and overlapping are conspicuous and follicular cells are usually larger than normal • Nuclear pleomorphism, and mitosis are uncommon • Cases that demonstrate nuclear features of Papillary carcinoma are excluded from this category • If sample is cellular and mostly macro follicles benign interpretation is appropriate
  • 30.
  • 31.
  • 32.
  • 33. Category V (Suspicious for malignancy) • If only 1 or 2 characteristics of malignancy are present, if they are only focal or if sample is sparsely cellular and a malignant diagnosis cannot be made with certainty
  • 34.
  • 35. Category VI (Malignant) • This category is used whenever cytomorphological features are conclusive for malignancy • Descriptive comments that follow are used to sub classify malignancy and to summarize the results of special studies if any
  • 36.
  • 37. DIAGNOSTIC CATEGORY RISK OF MALIGNANCY USUAL MANAGEMENT ND/ UNS 1-4 % Repeat FNA with ultrasound guidance Benign 0-3 % Clinical Follow up AUS/ FLUS 5-15% Repeat FNA FN/ SFN 15-30% Surgical lobectomy Suspicious for Malignancy 60-75% Near total thyroidectomy / Surgical lobectomy Malignant 97-99% Near total thyroidectomy